Myra Waiman
Director/Board Member at iosBio Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jeffrey Drew | M | 61 |
iosBio Ltd.
iosBio Ltd. Packaged SoftwareTechnology Services iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza. | - |
Elliot Bland | M | - |
iosBio Ltd.
iosBio Ltd. Packaged SoftwareTechnology Services iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza. | - |
Peter J. Cozens | M | - |
iosBio Ltd.
iosBio Ltd. Packaged SoftwareTechnology Services iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza. | - |
Jeffrey Almond | M | - |
iosBio Ltd.
iosBio Ltd. Packaged SoftwareTechnology Services iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza. | - |
Wayne Channon | M | - |
iosBio Ltd.
iosBio Ltd. Packaged SoftwareTechnology Services iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza. | - |
James Hudleston | M | - |
iosBio Ltd.
iosBio Ltd. Packaged SoftwareTechnology Services iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 6 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Myra Waiman
- Personal Network